Novocure (NVCR) Misses Q4 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Novocure Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
February 24, 2022 7:00 AM ESTFull year 2021 net revenues of $535 million, an increase of 8% year-over-year
Invested record $201 million in 2021 in research and development initiatives intended to advance Tumor Treating Fields science and technology
ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the fourth quarter and full year ended December 31, 2021. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).
We founded Novocure to exploit the novel observation that... More
